US4781601046
© PR Newswire
03.06.2025
JNJ
LISTED
NYSE
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
News Preview
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms
Data show a nearly 50 percent reduction in disease progression in BRCA-altered mCSPC vs. current standard of care
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson & Jo...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
News Preview
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will ho...
Themefolio
Profiler
Peergroup
© BusinessWire
23.05.2025
JNJ
LISTED
NYSE
FDA Panel Reiterates the Cancer Risks of Talc
News Preview
A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer products such as gum, candy, rice and pharmaceuticals.
Many of the experts cited the more than 30 years of studies showing an association between talc use and ovarian cancer, whic...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
21.05.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 9:00 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
21.05.2025
JNJ
LISTED
NYSE
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
News Preview
ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study
If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myeloma
RARITAN, N.J., May 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food a...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
JNJ
LISTED
NYSE
Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails
News Preview
Following a third failed bankruptcy maneuver by Johnson & Johnson (NYSE: JNJ), trial lawyers with Dallas-based Nachawati Law Group have filed three new lawsuits on behalf of women who developed cancer after prolonged use of the company’s talc-based products.
The filings come as courts across the country prepare to restart proceedings in one o...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th, 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time.
This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website...
Themefolio
Profiler
Peergroup
© PR Newswire
09.05.2025
JNJ
LISTED
NYSE
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
News Preview
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16
Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill
SPRING HOUSE, Pa., May 9,...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
JNJ
LISTED
NYSE
Johnson & Johnson expands efforts to champion the nursing workforce globally
News Preview
Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the world. These efforts are part of J&J CareCommunity, a new social impact platform that focuses the resources and expertise of J&J and J&J Foundation to support nurses at every...
Themefolio
Profiler
Peergroup
© PR Newswire
05.05.2025
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
News Preview
TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis
Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn's disease
SAN DIEGO, May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ)...
Themefolio
Profiler
Peergroup
© PR Newswire
05.05.2025
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
News Preview
Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92
SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term ext...
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
News Preview
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older
IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies
gMG patients taking IMAAVY demonstra...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
28.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor...
Themefolio
Profiler
Peergroup
© PR Newswire
26.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
News Preview
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy
95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population...
Themefolio
Profiler
Peergroup
© PR Newswire
26.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
News Preview
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR
Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer
LAS VEGAS, April 26, 2025 /PRN...
Themefolio
Profiler
Peergroup
© PR Newswire
21.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
News Preview
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2)
Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer
RARITAN, N.J., April 21, 2025 /...
Themefolio
Profiler
Peergroup
© BusinessWire
16.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management will participate in a Fireside Chat at 1:35 p.m. Eastern Time.
This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.in...
Themefolio
Profiler
Peergroup
© BusinessWire
15.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
News Preview
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases.
At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per shar...
Themefolio
Profiler
Peergroup
© BusinessWire
15.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson Reports Q1 2025 Results
News Preview
Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson....
Themefolio
Profiler
Peergroup
© PR Newswire
10.04.2025
JNJ
LISTED
NYSE
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
News Preview
ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously
84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16...
Themefolio
Profiler
Peergroup
© PR Newswire
08.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)
News Preview
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label extension phase
Up to 128 weeks and 180 patient years of follow-up in the open-label extensiona confirm a safety profile consistent with the Phase 3 Vivacity...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13th, 2025. Management will participate in a Fireside Chat at 1:40 p.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An ar...
Themefolio
Profiler
Peergroup
© PR Newswire
04.04.2025
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
News Preview
TREMFYA® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study
Topline results demonstrate efficacy across multiple domains at Week 24, reinforcing TREMFYA® as a first-line treatment option for patients with active psoriatic arthritis...
Themefolio
Profiler
Peergroup
© BusinessWire
02.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
News Preview
Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine.
“At Johnson & Johnson, we are committed to transforming care for the millions o...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition
News Preview
Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies’ shareholders on March 27, 2025, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025.
The transaction is expected to acc...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
JNJ
LISTED
NYSE
Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts
News Preview
In a resounding victory for thousands of women who have suffered from ovarian cancer linked to Johnson & Johnson’s (NYSE:JNJ) talcum powder products, U.S. Bankruptcy Court Judge Christopher Lopez has rejected the company’s third attempt to shield itself from liability through bankruptcy.
The ruling clears the way for claimants to seek speedy...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
News Preview
Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE: JNJ) (the “Company”) subsidiary Red River Talc LLC (“Red River”) to confirm its proposed prepackaged bankruptcy plan—notwithstanding that it offered one of the largest settlements ever proposed in a mass tort bankruptcy and was su...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
News Preview
Median overall survival not yet reached with projected improvement of more than one year versus osimertinib
RARITAN, N.J., March 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study. Head-to-head compar...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
JNJ
LISTED
NYSE
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
News Preview
Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+
Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-AD...
Themefolio
Profiler
Peergroup
© BusinessWire
21.03.2025
JNJ
LISTED
NYSE
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
News Preview
Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years. This represents a 25% increase in investment compared to the previous four ye...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
JNJ
LISTED
NYSE
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
News Preview
TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen
Supported by data from the GALAXI study, TREMFYA® is the only IL-23i to show superiority versus STELARA® in all pooled endoscopic endpoints within a double-blinded registrational trial
TREMFYA® app...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
News Preview
Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib
Preventative dermatologic regimen meets primary endpoint and enhances patient experience
RARITAN, N.J., March 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced...
Themefolio
Profiler
Peergroup
© PR Newswire
18.03.2025
JNJ
LISTED
NYSE
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation
News Preview
Sjögren's disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments
The Company is actively enrolling patients in the Phase 3 DAFFODIL study
This marks the fourth nipocalimab FDA Fast Track designation
SPRING HOUSE, Pa., March 18, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today anno...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
JNJ
LISTED
NYSE
Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
News Preview
Phase 3 MARIPOSA study showed LAZCLUZE® plus RYBREVANT® significantly improved progression-free survival, reducing the risk of disease progression or death by 30 per cent versus osimertinib alone.1
TORONTO, March 10, 2025 /CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for LAZCL...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
JNJ
LISTED
NYSE
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
News Preview
Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study
Clinical response and remission rates continued to improve through Week 28, building on strong data recently reported for the plaque psoriasis...
Themefolio
Profiler
Peergroup
© PR Newswire
08.03.2025
JNJ
LISTED
NYSE
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
News Preview
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm
Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD
Topline results from Phase 3 ICONI...
Themefolio
Profiler
Peergroup
© BusinessWire
05.03.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
News Preview
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
JNJ
LISTED
NYSE
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
News Preview
Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are eff...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
News Preview
Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients
The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV induction
SPRING HOUSE, Pa., Feb. 21, 2025 /PR...
Themefolio
Profiler
Peergroup
© PR Newswire
13.02.2025
JNJ
LISTED
NYSE
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
News Preview
Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including autoantibodies, potentially without affecting other immune functions
SPRING HOUSE, Pa., Feb. 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the publication...
Themefolio
Profiler
Peergroup
© BusinessWire
03.02.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An...
Themefolio
Profiler
Peergroup
© PR Newswire
23.01.2025
JNJ
LISTED
NYSE
Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour
News Preview
Underscores the urgent need for improved diagnosis and clinical management of psoriasis in patients with skin of colour and enhanced treatment standards
TORONTO, Jan. 23, 2025 /CNW/ - Johnson & Johnson (NYSE: JNJ) is proud to a...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
JNJ
LISTED
NYSE
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
News Preview
Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “As a healthc...
Themefolio
Profiler
Peergroup
© PR Newswire
21.01.2025
JNJ
LISTED
NYSE
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
News Preview
Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours1
SPRAVATO® alone showed a rapid and superior improvement vs. placebo in the Montgomery-Asberg Depression Rating...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2025
JNJ
LISTED
NYSE
RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer
News Preview
Phase 3 MARIPOSA-2 study showed RYBREVANT® in combination with carboplatin and pemetrexed significantly improved progression-free survival compared to carboplatin and pemetrexed alone.1
TORONTO, Jan. 16, 2025 /CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for RYBREVANT® (amivan...
Themefolio
Profiler
Peergroup
© PR Newswire
15.01.2025
JNJ
LISTED
NYSE
New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer
News Preview
Application accepted for U.S. FDA Real-Time Oncology Review (RTOR) based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1
RARITAN, N.J., Jan. 15, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced it has initiated the submission of an original New Drug Application with the U.S. Food an...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
JNJ
LISTED
NYSE
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
News Preview
Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for ce...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
JNJ
LISTED
NYSE
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
News Preview
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations
Fast Track designations reinforce J&J's commitment to Alzheimer's disease development and the potential of its precision approach
TITUSVILLE, N.J., Jan. 8, 2025 /PRNewswire/ -- Johnson &a...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib
News Preview
Median overall survival improvement expected to exceed one year
First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
RARITAN, N.J., Jan. 7, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in can...
Themefolio
Profiler
Peergroup
© BusinessWire
02.01.2025
JNJ
LISTED
NYSE
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
News Preview
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2025 of $1.24 per share on the company’s common stock. The dividend is payable on March 4, 2025 to shareholders of record at the close of business on February 18, 2025. The ex-dividend date is February 18, 2025.
Abo...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:00 p.m. (Eastern Time).
This live audio webcast will be availa...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
JNJ
LISTED
NYSE
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
News Preview
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will hos...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2024
JNJ
LISTED
NYSE
CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study
News Preview
89 percent of patients evaluable for MRD assessment were MRD negative, with the majority reaching MRD negativity in less than 2 months
Results add to the overall survival (OS) benefits recently presented, as the first and only cell therapy to significantly extend OS versus standard therapies in multiple myeloma
SAN DIEGO, Dec. 9, 2024 /PRNewswir...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
JNJ
LISTED
NYSE
Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options
News Preview
Abstracts presented at ASH 2024 provide insight into the patient experience given the unpredictable nature of wAIHA, a rare autoantibody disease, and the uncertainty of current treatment approaches used to manage the condition
There are no FDA-approved therapies indicated for wAIHA, and patients living with this condition need targeted treatment...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
JNJ
LISTED
NYSE
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma
News Preview
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years
Subgroup analysis from Phase 3 AURIGA study show higher rates of MRD-negative conversion in patient populations disproportionately impacted by multiple myeloma
SAN DIEGO, Dec. 8, 2...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2024
JNJ
LISTED
NYSE
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
News Preview
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy
SAN DIEGO, Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational st...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2024
JNJ
LISTED
NYSE
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
News Preview
First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study
SAN DIEGO, Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 AQUILA study showing that DARZALEX F...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2024
JNJ
LISTED
NYSE
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)
News Preview
Applications filed for TREMFYA® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis
SPRING HOUSE, Pa., Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking...
Themefolio
Profiler
Peergroup
© PR Newswire
22.11.2024
JNJ
LISTED
NYSE
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
News Preview
Following recent U.S. FDA approval of TREMFYA® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that offers choice of subcutaneous or intravenous induction in UC
Submission is supported by the Phase 3 ASTRO study, which achieved the primary endpoint of...
Themefolio
Profiler
Peergroup
© PR Newswire
21.11.2024
JNJ
LISTED
NYSE
Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
News Preview
Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to standard of care.1
TORONTO, Nov. 21, 2024 /CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
